|
Policy Matters: August 2017
|
|
|
Announcements and Features
|
|
Duke-Margolis welcomes Gillian Sanders Schmidler, PhD, as Deputy Director, Academics
Gillian Sanders Schmidler, PhD, will be joining Duke-Margolis as Deputy Director, Academics. In this role she will guide and help develop our academic research activities, oversee research proposal development, help us recruit, retain and develop high-potential research faculty, and oversee and support the expanding education programs for the Center. She will work with our affiliated faculty to ensure strong mentorship of junior faculty, graduate students and fellows, as well as work to increase research collaboration and communication.
Read More
|
|
Save the date! mHealth Public Event
The mHealth Working Group met for an
all-day meeting in Washington, DC, on July 20, 2017 to speak about inclusion of data from apps and wearables to complement existing real-world data sources (registries, electronic health records, medical claims, etc.). Their recommendations on advancing the use of data from mHealth apps and wearables for secondary research on the evaluation and surveillance of medical projects will be released during a public event on
September 15th, from 2-4pm in the 1201 Pennsylvania Avenue large conference room on the ground floor.
|
|
Duke-Margolis Proposes Economic Incentives for Antimicrobial Drugs
Read the JAMA viewpoint.
On August 4, the biomedical innovation team released a paper describing U.S. policy approaches that could provide better economic incentives to antimicrobial developers that successfully bring effective drugs to the market, providing a societal benefit that exceeds the cost of the incentive.
Resistance to current antimicrobial drugs is a growing source of morbidity, mortality, and healthcare costs. Challenging market dynamics have led to a weak pipeline of drug candidates to respond to these threats. Combined, these two trends represent a significant and growing threat to US and global health preparedness and lead to direct and indirect costs estimated at more than $35 billion annually.
The Priority Antimicrobial Value and Entry (PAVE) Award proposal, formulated by a team led by Center deputy director Gregory Daniel, PhD, MPH, combines a market entry reward with population-based payments that phase in over time. The market entry reward provides public funds over early years of marketing after FDA approval, as an incentive to antimicrobial developers to bring high-priority antimicrobials to market for unmet medical needs. To receive the full payments, the developer must work with health plans and providers to get revenue from payment contracts that are linked to value and appropriate use of the antimicrobial in practice, not volume-based payments that lead to overuse and diminished effectiveness. Read More
|
Pandemics and the Poor
Duke-Margolis and DGHI member Gavin Yamey and Ben Oppenheim of the Brookings Institution co-authored a blog post putting forward a four-point plan for protecting the poor from pandemic disease outbreaks. Pandemics disproportionately affect the poor in terms of morbidity and mortality and economic circumstances. Read more
|
|
Growth Of ACOs And Alternative Payment Models In 2017
Accountable care is an important mechanism used by public and private payers to align health care provider payments with efficient care for defined patient populations. David Muhlestein of Leavitt Partners, Duke-Margolis Director
Mark McClellan and Research Director
Robert Saunders track the progress of Accountable Care Organizations on the
Health Affairs Blog.
|
|
|
Awards, Honors and Presentations
|
|
|
Duke-Margolis Director
Mark B. McClellan, MD, PhD, moderated a flagship panel and Deputy Director
Gregory Daniel, PhD, presented policy proposals for providing incentives for development of new antimicrobial drugs in several sessions at the
2017 BIO International Convention in San Diego on June 21. Dr. Daniel was an invited speaker for the National Academics of Medicine's workshop on combating antimicrobial resistance. Dr. McClellan also appeared on a panel with
Research!America, "A world without disease: can we get there?"
In addition,
Dr. Daniel
was an invited speaker at the DIA Annual Meeting in June, where he also moderated a panel and at the National Academies, where he spoke at a workshop focusing on Antimicrobial Resistance. He has a number of upcoming speaking engagements on the same topic, including at the DRIVE-AB meeting in September.
|
|
|
The following Duke-Margolis faculty and staff participated in the AcademyHealth national meeting, including:
- Charlene Wong, MD, MSPH: Platform presentation “BE in CONTROL - Behavioral Economic Incentives to Improve Glycemic Control among Adolescents and Young Adults with Type 1 Diabetes: A RCT.” Dr. Wong also co-chaired the conference planning for the theme “Consumer choice & incentives,” and led a session entitled “Improving Health Behaviors through Financial and Social Incentives.”
- Will Bleser, PhD, MSPH: Platform presentation “A multi-methods examination of ACOs: What affects ACO performance and survival?” He also co-authored a poster with Robert Saunders, PhD, “Longitudinal analysis of MSSP ACO utilization and expenditures: Are ACO spending patterns changing?
- Andrew Olson, MPP, and Nrupen Bhavsar presented a poster, "Defining the end of life health care markets”
|
|
|
Interesting Project? Funding Opportunities? News and Events? Awards and Honors?
Policy Impact? Op Eds?
We're looking for ways to highlight your accomplishments and share information.
|
|
|
|
|
|
|
